FH:CC - Filament Health receives authorization from Health Canada for Phase 2 clinical trial at UBC

(NewsDirect)

Filament Health CEO Ben Lightburn joinedSteve Darling from Proactive to share the news that the company hasreceived approval from Health Canada for a phase 2 clinical trial,which will be conducted at the University of British Columbia.

This groundbreaking trial will focus oninvestigating the effects of PEX010, a botanical psilocybin drugcandidate developed by Filament, specifically in the context oftreating opioid use disorder (OUD).

Lightburn explained that the primary objectives of this phase 2clinical trial are to assess the safety and feasibility ofadministering psilocybin as a potential treatment for OUD and toevaluate any significant changes in participants' opioid use.

The approval of this trial marks asignificant step forward in Filament Health's mission to exploreinnovative and effective interventions for individuals grappling withOUD.

Furthermore, Lightburnemphasized the pressing need for research into novel interventions tosupport those suffering from opioid use disorder. Research thus farhas suggested that psychedelic-assisted therapy, such as thatinvolving psilocybin, holds promise as a potentially groundbreakingapproach to address this complex and challenging issue.

Insummary, Filament Health's approval for a phase 2 clinical trialby Health Canada represents a pivotal moment in their commitment toadvancing the field of psychedelic-assisted therapy. By investigatingthe potential of PEX010 in the treatment of opioid use disorder, thecompany is contributing to the broader scientific understanding of howpsychedelics may offer hope and innovative solutions for individualsfacing this critical healthcare challenge.

ContactDetails

Proactive Investors

+1 604-688-8158

na-editorial@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.